How to recognize late-onset hypogonadism in men with sexual dysfunction - PubMed (original) (raw)
Review
How to recognize late-onset hypogonadism in men with sexual dysfunction
Giovanni Corona et al. Asian J Androl. 2012 Mar.
Abstract
Late-onset hypogonadism (LOH) has been considered the most common form of male hypogonadism with a prevalence of approximately 1 in 100 men. Diagnosis of LOH should be made in symptomatic men with unequivocally low serum testosterone (T) levels. However, its clinical presentation is often insidious and difficult to recognize because it is characterized by nonspecific symptoms that make differential diagnosis with physiological ageing problematic. Sexual dysfunction is the most important determinant for medical consultation and the most specific symptom associated with low T. We therefore analysed a consecutive series of 1734 subjects who attended our unit for sexual dysfunction to investigate the associations between low T (different thresholds), sexual parameters, medical history data (delayed puberty, pituitary disease or cryptorchidism) and their physical exam results. Metabolic parameters, in particular waist circumference, display the greatest accuracy in detecting low T. We found that only the association of several symptoms and signs could significantly raise the clinical suspicion of low T. Structured inventories, which cluster together symptoms and signs of hypogonadism, can help clinicians suspect androgen deficiency. In particular, structured interviews, such as ANDROTEST, have been demonstrated to have a greater accuracy when compared to self reported questionnaires in detecting low T levels.
Figures
Figure 1
Conditions with a high prevalence of low testosterone levels for which measurement of serum testosterone levels is advisable.
Figure 2
Relevant metrics in patients' medical and sexual histories for detecting mild (<12 nmol l−1) and severe (<8 nmol l−1) hypogonadism in a consecutive series of 1734 patients that attended our unit seeking medical care for sexual dysfunction between 2002 and 2010. Data are reported in a log scale as age-adjusted hazard ratio (95% confidence intervals) stratified by age (<53 years old (a) and ≥53 years old(b)).
Figure 3
Relevant items in sexual history for detecting mild (<12 nmol l−1) and severe (<8 nmol l−1) hypogonadism in a consecutive series of 1734 patients that attended our unit seeking medical care for sexual dysfunction between 2002 and 2010. Data are reported in a log scale as age-adjusted hazard ratio (95% confidence intervals) stratified by age (<53 years old (a) and ≥53 years old(b)).
Figure 4
Clinical, metabolic and instrumental metrics for detecting mild (<12 nmol l−1) and severe (<8 nmol −1) hypogonadism in a consecutive series of 1734 patients that attended our unit seeking medical care for sexual dysfunction between 2002 and 2010. Data are reported in a log scale as age-adjusted hazard ratio (95% confidence intervals) stratified by age (<53 years old (a) and ≥53 years old(b)). NCEP-ATPIII, National Cholesterol Education Program's Adult Treatment Panel III; PSV, peak systolic velocity at penile Doppler ultrasound; T2DM, type 2 diabetes mellitus.
Figure 5
Area under the curve (95% confidence intervals) derived from receiver-operating characteristic (ROC) curves for severe (total testosterone (TT)<8 nmol l−1) or mild (TT<12 nmol −1) hypogonadism compared to different metrics derived from patients' medical and sexual history. Data are stratified by age (<53 years old (a) and ≥53 years old(b)).
Figure 6
Area under the curve (95% confidence intervals) derived from receiver-operating characteristic (ROC) curves for severe (total testosterone (TT)<8 nmol −1) or mild (TT<12 nmol l−1) hypogonadism compared to different metrics derived from sexual history. Data are stratified by age (<53 years old (a) and ≥53 years old(b)).
Figure 7
Area under the curve (95% confidence intervals) derived from receiver-operating characteristic (ROC) curves for severe (total testosterone (TT)<8 nmol l−1) or mild (TT<12 nmol l−1) hypogonadism compared to different measurements derived from clinical, metabolic and instrumental items. Data are stratified by age (<53 years old (a) and ≥53 years old(b)). NCEP-ATPIII, National Cholesterol Education Program's Adult Treatment Panel III; PSV, peak systolic velocity; T2DM, type 2 diabetes mellitus.
Figure 8
ROC curves for severe hypogonadism (total testosterone (T)<8 nmol l−1 or calculated free T according to Vermuelen's formula <225 pmol l−1) in relation to ANDROTEST score. All data were derived from a consecutive series of subjects attending our unit from 2002 to 2010 seeking medical care for sexual dysfunction. Total T and calculated free T were available for 1734 and 1467 subjects, respectively.
Similar articles
- Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS).
Tajar A, Huhtaniemi IT, O'Neill TW, Finn JD, Pye SR, Lee DM, Bartfai G, Boonen S, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Labrie F, Lean ME, Pendleton N, Punab M, Vanderschueren D, Wu FC; EMAS Group. Tajar A, et al. J Clin Endocrinol Metab. 2012 May;97(5):1508-16. doi: 10.1210/jc.2011-2513. Epub 2012 Mar 14. J Clin Endocrinol Metab. 2012. PMID: 22419720 - Both comorbidity burden and low testosterone can explain symptoms and signs of testosterone deficiency in men consulting for sexual dysfunction.
Rastrelli G, Corona G, Maggi M. Rastrelli G, et al. Asian J Androl. 2020 May-Jun;22(3):265-273. doi: 10.4103/aja.aja_61_19. Asian J Androl. 2020. PMID: 31249270 Free PMC article. - The relationship of testosterone to prostate-specific antigen in men with sexual dysfunction.
Corona G, Boddi V, Lotti F, Gacci M, Carini M, De Vita G, Sforza A, Forti G, Mannucci E, Maggi M. Corona G, et al. J Sex Med. 2010 Jan;7(1 Pt 1):284-92. doi: 10.1111/j.1743-6109.2009.01549.x. Epub 2009 Nov 13. J Sex Med. 2010. PMID: 19912506 - Diagnosis of hypogonadism in ageing men.
Kaufman JM. Kaufman JM. Rev Endocr Metab Disord. 2022 Dec;23(6):1139-1150. doi: 10.1007/s11154-022-09763-4. Epub 2022 Nov 10. Rev Endocr Metab Disord. 2022. PMID: 36355322 Review. - Which patients with sexual dysfunction are suitable for testosterone replacement therapy?
Morelli A, Corona G, Filippi S, Ambrosini S, Forti G, Vignozzi L, Maggi M. Morelli A, et al. J Endocrinol Invest. 2007 Nov;30(10):880-8. doi: 10.1007/BF03349232. J Endocrinol Invest. 2007. PMID: 18075293 Review.
Cited by
- Increased risk of testosterone deficiency is associated with the systemic immune-inflammation index: a population-based cohort study.
Li Y, Liu M, Cui Y, Zhu Z, Chen J, Zeng F, Gao M, Li Y, Huang F, Chen H. Li Y, et al. Front Endocrinol (Lausanne). 2022 Aug 16;13:974773. doi: 10.3389/fendo.2022.974773. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36051392 Free PMC article. - Administration of increasing doses of gonadotropin-releasing hormone in men with spinal cord injury to investigate dysfunction of the hypothalamic-pituitary-gonadal axis.
Bauman WA, La Fountaine MF, Cirnigliaro CM, Kirshblum SC, Spungen AM. Bauman WA, et al. Spinal Cord. 2018 Mar;56(3):247-258. doi: 10.1038/s41393-017-0002-x. Epub 2017 Nov 15. Spinal Cord. 2018. PMID: 29142294 Free PMC article. Clinical Trial. - Enclomiphene citrate for the treatment of secondary male hypogonadism.
Rodriguez KM, Pastuszak AW, Lipshultz LI. Rodriguez KM, et al. Expert Opin Pharmacother. 2016 Aug;17(11):1561-7. doi: 10.1080/14656566.2016.1204294. Epub 2016 Jul 4. Expert Opin Pharmacother. 2016. PMID: 27337642 Free PMC article. Review. - Endocrine evaluation of erectile dysfunction.
Sansone A, Romanelli F, Gianfrilli D, Lenzi A. Sansone A, et al. Endocrine. 2014 Aug;46(3):423-30. doi: 10.1007/s12020-014-0254-6. Epub 2014 Apr 6. Endocrine. 2014. PMID: 24705931 Review. - Metabolic Disorders and Male Hypogonadotropic Hypogonadism.
Pivonello R, Menafra D, Riccio E, Garifalos F, Mazzella M, de Angelis C, Colao A. Pivonello R, et al. Front Endocrinol (Lausanne). 2019 Jul 25;10:345. doi: 10.3389/fendo.2019.00345. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 31402895 Free PMC article. Review.
References
- Tajar A, Forti G, O'Neill TW, Lee DM, Silman AJ, et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab. 2010;95:1810–8. - PubMed
- Buvat J, Maggi M, Gooren L, Guay AT, Kaufman J, et al. Endocrine aspects of male sexual dysfunctions. In: Montorsi F, Basson R, Adaikan G, Becher E, Clayton A, Giuliano G, Khoury S, Sharlip I, editors. Sexual Medicine, Sexual Dysfunctions in Men and Women. Proceedings of the 3rd International Consultation on Sexual Medicine Paris; Health Publication Ltd; 2010. p681. - PubMed
- Morelli A, Corona G, Filippi S, Ambrosini S, Forti G, et al. Which patients with sexual dysfunction are suitable for testosterone replacement therapy. J Endocrinol Invest. 2007;30:880–8. - PubMed
- Corona G, Rastrelli G, Forti G, Maggi M. Update in testosterone therapy for men. J Sex Med. 2011;8:639–54. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical